SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages E538-E547

  Bhardwaj, Abhishek ^a   Das, Sanjeev ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Deacetylation; PKM2; SIRT6; Tumor suppressor

Indexed keywords

GLYCOLYTIC ENZYME; PYRUVATE KINASE M2; SIRTUIN 6; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE PROTEIN; SIRT6 PROTEIN, HUMAN; SIRTUIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; ACETYLATION; ANIMAL; CELL NUCLEUS; HEP-G2 CELL LINE; METABOLISM; ONCOGENE; PHYSIOLOGY; PROTEIN TRANSPORT;

ACETYLATION; ANIMALS; CARRIER PROTEINS; CELL NUCLEUS; HEP G2 CELLS; HUMANS; MEMBRANE PROTEINS; MICE; ONCOGENES; PROTEIN TRANSPORT; SIRTUINS; THYROID HORMONES;

EID: 84956611826     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520045113     Document Type: Article

References (34)

1. Michishita E, et al. (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452(7186):492-496.
2. Michishita E, et al. (2009) Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle 8(16):2664-2666.
3. Kawahara TL, et al. (2009) SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136(1):62-74.
4. Zhong L, et al. (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140(2):280-293.
5. Kaidi A, Weinert BT, Choudhary C, Jackson SP (2010) Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 329(5997):1348-1353.
6. Mao Z, et al. (2011) SIRT6 promotes DNA repair under stress by activating PARP1. Science 332(6036):1443-1446.
7. Sebastián C, et al. (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6):1185-1199.
8. Min L, et al. (2012) Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 14(11):1203-1211.
9. Marquardt JU, et al. (2013) Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 58(3):1054-1064.
10. Kugel S, et al. (2015) Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer. Cell Reports 13(3):479-488.
11. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452(7184):181-186.
12. Desai S, et al. (2014) Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5(18):8202-8210.
13. Xu Q, Liu X, Zheng X, Yao Y, Liu Q (2014) PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol Lett 8(5):1973-1979.
14. Steták A, et al. (2007) Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 67(4):1602-1608.
15. Hoshino A, Hirst JA, Fujii H (2007) Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem 282(24):17706-17711.
16. Yang W, et al. (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480(7375):118-122.
17. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45(5):598-609.
18. Yang W, et al. (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685-696.
19. Lv L, et al. (2013) Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 52(3):340-352.
20. Kanfi Y, et al. (2008) Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett 582(5):543-548.
21. Kim HS, et al. (2010) Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab 12(3):224-236.
22. Lv L, et al. (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42(6):719-730.
23. Pemberton LF, Paschal BM (2005) Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 6(3):187-198.
24. Dominy JE, Jr, et al. (2012) The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell 48(6):900-913.
25. Mazurek S (2011) Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43(7):969-980.
26. Tamada M, Suematsu M, Saya H (2012) Pyruvate kinase M2: Multiple faces for conferring benefits on cancer cells. Clin Cancer Res 18(20):5554-5561.
27. Spoden GA, et al. (2009) The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J Cell Biochem 107(2):293-302.
28. Yang W, et al. (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14(12):1295-1304.
29. Lipowsky G, et al. (2000) Exportin 4: A mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J 19(16):4362-4371.
30. Kurisaki A, et al. (2006) The mechanism of nuclear export of Smad3 involves exportin 4 and Ran. Mol Cell Biol 26(4):1318-1332.
31. Groisman R, et al. (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113(3):357-367.
32. Das S, Somasundaram K (2006) Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo. Cancer Biol Ther 5(2):210-217.
33. Jones RG, et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3):283-293.
34. Lei Q, et al. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9(5):367-378.